WO2009007677A3 - Dsb repair- inhibitors as anti-tumour agents - Google Patents

Dsb repair- inhibitors as anti-tumour agents Download PDF

Info

Publication number
WO2009007677A3
WO2009007677A3 PCT/GB2008/002224 GB2008002224W WO2009007677A3 WO 2009007677 A3 WO2009007677 A3 WO 2009007677A3 GB 2008002224 W GB2008002224 W GB 2008002224W WO 2009007677 A3 WO2009007677 A3 WO 2009007677A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
dsb repair
tumour agents
cancer
tumour
Prior art date
Application number
PCT/GB2008/002224
Other languages
French (fr)
Other versions
WO2009007677A2 (en
Inventor
Conchita Vens
Adrian Campbell Begg
Original Assignee
Stichting Het Nederlands Kanker Instituut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Het Nederlands Kanker Instituut filed Critical Stichting Het Nederlands Kanker Instituut
Publication of WO2009007677A2 publication Critical patent/WO2009007677A2/en
Publication of WO2009007677A3 publication Critical patent/WO2009007677A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided a use of a DSB repair-inhibitor in the manufacture of a medicament for use in the treatment of a cancer in an individual, wherein the cancer comprises cells which are/is deficient in a BER and/or a SSBR pathway.
PCT/GB2008/002224 2007-07-06 2008-06-27 Anti-tumour methods WO2009007677A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0713192.3A GB0713192D0 (en) 2007-07-06 2007-07-06 Anti-tumour methods
GB0713192.3 2007-07-06

Publications (2)

Publication Number Publication Date
WO2009007677A2 WO2009007677A2 (en) 2009-01-15
WO2009007677A3 true WO2009007677A3 (en) 2009-11-26

Family

ID=38440558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002224 WO2009007677A2 (en) 2007-07-06 2008-06-27 Anti-tumour methods

Country Status (2)

Country Link
GB (1) GB0713192D0 (en)
WO (1) WO2009007677A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764234C (en) 2009-06-04 2019-03-12 The Governors Of The University Of Alberta Small molecule inhibitors of polynucleotide kinase/phosphatase, poly(adp-ribose) polymerase and uses thereof
EP2753716B1 (en) 2011-09-08 2017-11-01 Yeda Research and Development Co. Ltd. Novel risk biomarkers for lung cancer
CN106995840B (en) * 2017-03-20 2020-05-05 山东师范大学 Method for detecting activity of thymine DNA glycosylase based on double-signal amplification strategy mediated by cyclic enzyme repair
CN110408694A (en) * 2018-04-26 2019-11-05 胤安国际（辽宁）基因科技股份有限公司 Temozolomide is assessed in the new method of the sensibility for the treatment of Patients with gliomas
CN109321658B (en) * 2018-11-23 2021-09-07 浙江大学 Kit for detecting susceptibility of cervical cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066624A2 (en) * 2006-10-20 2008-06-05 Dana-Farber Cancer Institute Dna damage repair inhibitors and methods for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066624A2 (en) * 2006-10-20 2008-06-05 Dana-Farber Cancer Institute Dna damage repair inhibitors and methods for treating cancer

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BREM R ET AL: "The methyl methanesulfonate induced S-phase delay in XRCC1-deficient cells requires ATM and ATR", DNA REPAIR, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 6, 1 June 2008 (2008-06-01), pages 849 - 857, XP022679612, ISSN: 1568-7864, [retrieved on 20080328] *
BUSCH DAVID B ET AL: "Phenotype of FAECB (Facility for Automated Experiments in Cell Biology) Chinese hamster ovary mutants with minimal UV-sensitivity", MUTATION RESEARCH, vol. 487, no. 1-2, 1 November 2001 (2001-11-01), pages 31 - 39, XP002494923, ISSN: 0027-5107 *
COWELL IAN G ET AL: "Small molecule inhibitors of DNA-PKcs and ATM inhibit DNA repair and sensitize cells to ionizing radiation.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 1039, XP002494990, ISSN: 0197-016X *
CRUL MIRJAM ET AL: "DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.", BIOCHEMICAL PHARMACOLOGY, vol. 65, no. 2, 15 January 2003 (2003-01-15), pages 275 - 282, XP002544232, ISSN: 0006-2952 *
HORTON ET AL: "Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency", DNA REPAIR, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 4, 8 March 2007 (2007-03-08), pages 530 - 543, XP005918201, ISSN: 1568-7864 *
HOY C A ET AL: "RAPID DETECTION OF DNA-DAMAGING AGENTS USING REPAIR-DEFICIENT CHO CHINESE HAMSTER OVARY CELLS", MUTATION RESEARCH, vol. 130, no. 5, 1984, pages 321 - 332, XP009105462, ISSN: 0027-5107 *
IKEJIMA M ET AL: "Poly(ADP-ribose) metabolism appears normal in EM9, a mutagen-sensitive mutant of CHO cells", MUTATION RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 128, no. 2, 1 September 1984 (1984-09-01), pages 213 - 220, XP023422070, ISSN: 0027-5107, [retrieved on 19840901] *
NOGUCHI ET AL: "Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygelda namycin", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 351, no. 3, 11 November 2006 (2006-11-11), pages 658 - 663, XP005726085, ISSN: 0006-291X *
TAVERNA PIETRO ET AL: "Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.", CANCER RESEARCH, vol. 63, no. 4, 15 February 2003 (2003-02-15), pages 838 - 846, XP002494964, ISSN: 0008-5472 *
VERMEULEN ET AL: "Role for DNA polymerase beta in response to ionizing radiation", DNA REPAIR, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 2, 13 January 2007 (2007-01-13), pages 202 - 212, XP005829717, ISSN: 1568-7864 *
WACHTERS F M ET AL: "SELECTIVE TARGETING OF HOMOLOGOUS DNA RECOMBINATION REPAIR BY GEMCITABINE", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 57, no. 2, 1 October 2003 (2003-10-01), pages 553 - 562, XP001206011, ISSN: 0360-3016 *

Also Published As

Publication number Publication date
GB0713192D0 (en) 2007-08-15
WO2009007677A2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
AU319251S (en) Tractor
WO2007121131A3 (en) Medical devices including shape memory materials
WO2008034013A3 (en) Medical devices and methods of making the same
EP2109668A4 (en) Human cancer stem cells
WO2008054676A3 (en) Medical devices and methods of using the same
WO2008016667A3 (en) Methods to prepare polymer blend implantable medical devices
WO2009011889A3 (en) Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2008066784A3 (en) Expression of foxp3 by cancer cells
EP2160152A4 (en) Combined fibrinolytic and antimicrobial catheter and uses thereof
WO2007124855A8 (en) Antiseptic-containing silicone elastomers
WO2008027600A3 (en) Imatinib compositions
AU2008263581A8 (en) Well treatment
CA125778S (en) Lid with spatula
PT2147122E (en) Enzymatic anticancer therapy
AU317011S (en) Tractor
WO2009007677A3 (en) Dsb repair- inhibitors as anti-tumour agents
AU316949S (en) Toothbrush
CA124077S (en) Paper tissue
WO2009074253A3 (en) Clofarabine dietherphospholipid derivatives
WO2008103431A3 (en) Dnai - liposomes
EP2120896B8 (en) Medically active plaster
WO2010045896A3 (en) Polymeric composition with synergistic effect in treatment of tumour diseases
AU312301S (en) Charger
CA125779S (en) Spatula
AU318613S (en) Seat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08775782

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08775782

Country of ref document: EP

Kind code of ref document: A2